SecSonar.com

Celldex Therapeutics, Inc. (CLDX)

Celldex Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Celldex Therapeutics, Inc. (CLDX) is a Biotechnology company based in US with a market capitalization of $2.1B. Revenue declined 78.6% year-over-year and free cash flow was negative at -$213.7M. This page tracks CLDX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 186 employees · IPO May 15, 1986

Valuation

Valuation & price

$31.34 · as of May 17, 2026 · -18.3% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

3.99

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$38.37$29.19$20.01Jul 25Dec 25Jul 26Jul 7, 25$20.98Jul 9, 25$22.46Jul 11, 25$22.91Jul 15, 25$22.85Jul 17, 25$22.97Jul 21, 25$22.06Jul 23, 25$23.87Jul 25, 25$23.35Jul 29, 25$21.95Jul 31, 25$21.98Aug 4, 25$21.80Aug 6, 25$21.44Aug 11, 25$20.01Aug 13, 25$24.99Aug 15, 25$25.50Aug 19, 25$24.02Aug 21, 25$22.02Aug 25, 25$21.93Aug 27, 25$22.60Aug 29, 25$22.08Sep 3, 25$23.61Sep 5, 25$22.87Sep 9, 25$24.30Sep 11, 25$25.20Sep 16, 25$24.58Sep 18, 25$25.92Sep 22, 25$24.86Sep 24, 25$25.60Sep 26, 25$26.14Sep 30, 25$25.87Oct 2, 25$25.85Oct 6, 25$26.38Oct 8, 25$27.24Oct 10, 25$26.77Oct 14, 25$26.47Oct 16, 25$26.55Oct 21, 25$27.91Oct 23, 25$26.26Oct 27, 25$27.37Oct 29, 25$25.99Oct 31, 25$26.73Nov 4, 25$23.85Nov 6, 25$23.26Nov 10, 25$22.67Nov 12, 25$24.25Nov 14, 25$25.55Nov 18, 25$25.58Nov 20, 25$25.07Nov 25, 25$26.44Nov 28, 25$27.02Dec 2, 25$26.67Dec 4, 25$29.60Dec 8, 25$29.80Dec 10, 25$28.19Dec 12, 25$27.51Dec 16, 25$26.68Dec 18, 25$25.29Dec 22, 25$27.27Dec 24, 25$26.83Dec 29, 25$26.03Jan 2, 26$27.01Jan 6, 26$26.28Jan 8, 26$27.35Jan 12, 26$25.67Jan 14, 26$26.34Jan 16, 26$25.65Jan 21, 26$26.17Jan 23, 26$25.92Jan 27, 26$26.23Jan 29, 26$24.69Feb 2, 26$24.66Feb 4, 26$24.27Feb 9, 26$24.81Feb 11, 26$24.60Feb 13, 26$23.00Feb 18, 26$23.00Feb 20, 26$23.02Feb 24, 26$24.84Feb 26, 26$30.64Mar 2, 26$30.00Mar 4, 26$29.54Mar 6, 26$29.43Mar 10, 26$31.15Mar 12, 26$29.88Mar 17, 26$29.64Mar 19, 26$30.03Mar 23, 26$31.80Mar 25, 26$31.68Mar 27, 26$30.30Mar 31, 26$31.72Apr 2, 26$31.06Apr 7, 26$31.35Apr 9, 26$33.62Apr 13, 26$32.59Apr 15, 26$33.87Apr 17, 26$34.55Apr 22, 26$34.21Apr 24, 26$33.29Apr 28, 26$33.23Apr 30, 26$32.88May 4, 26$32.77May 6, 26$34.39May 8, 26$33.97May 12, 26$32.00May 14, 26$32.45May 18, 26$30.22May 20, 26$30.90May 22, 26$30.73May 28, 26$31.70Jun 1, 26$30.14Jun 3, 26$29.77Jun 5, 26$28.62Jun 9, 26$29.60Jun 11, 26$29.96Jun 15, 26$32.12Jun 17, 26$32.93Jun 22, 26$33.41Jun 24, 26$33.78Jun 26, 26$35.26Jul 2, 26$38.37
$20.0152-week range$38.37
Loading valuation history…

Fundamentals

Key fundamentals

$2.1B

Market cap

-78.6%

Revenue growth (YoY)

100.0%

Gross margin

-$213.7M

Free cash flow (USD)

-$516.2M

Net debt

Net cash position

3.3%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$6.8MFY 2017$12.7MFY 2018$9.5MFY 2019$3.6MFY 2020$7.4MFY 2021$4.7MFY 2022$2.4MFY 2023$6.9MFY 2024$7.0MFY 2025$1.5M
$6.8M$1.5M

Free cash flow by year

2016 → 2025

FY 2016$-115.8MFY 2017$-101.7MFY 2018$-76.0MFY 2019$-47.1MFY 2020$-42.0MFY 2021$-62.2MFY 2022$-105.6MFY 2023$-109.1MFY 2024$-159.7MFY 2025$-213.7M
-$115.8M-$213.7M

Gross margin by year

2021 → 2025

FY 2021-1046.2%FY 2022-3389.9%FY 2023-1614.5%FY 2024-2229.8%FY 2025100.0%
-1046.2%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventStockholder Meeting ResultsJun 26, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventCommon Stock OfferingApr 2, 2026Filing

Questions

Frequently asked questions

What is Celldex Therapeutics, Inc.'s market cap?

Celldex Therapeutics, Inc. (CLDX) has a market capitalization of $2.1B.

What is CLDX's P/E ratio?

A meaningful P/E ratio is not available for CLDX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is CLDX's price-to-book (P/B) ratio?

CLDX trades at 3.99 times book value per share.

Are insiders buying CLDX stock?

SEC Form 4 filings show no open-market insider buys at Celldex Therapeutics, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

IMNM

Immunome, Inc.

$2.1B

NBTX

Nanobiotix S.A.

$2B

OCUL

Ocular Therapeutix, Inc.

$2B

ZLAB

Zai Lab Limited

$2B

MESO

Mesoblast Limited

$2B

AUPH

Aurinia Pharmaceuticals Inc.

$2B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.